

Applicants: David Stern and Ann-Marie Schmidt
Serial No.: 08/905,709
Filing Date: August 5, 1997
Page 3

crit
E2
Cont
F2
and RAGE in an amount effective to prevent
atherosclerosis in the subject.--

E3
--16. (Amended) The method of claim 1, wherein the administering
is effected by intralesional, intraperitoneal,
intramuscular or intravenous injection, infusion,
liposome-mediated delivery, or topical, nasal, oral,
ocular or otic delivery.--

--36. (New) The method of claim 1, wherein the hyperlipidemia is
hypercholesterolemia.--

E4
--37. (New) The method of claim 1, wherein the hyperlipidemia is
hypertriglyceridemia.--

--38. The method of claim 1, wherein the agent is a soluble
extracellular portion of a receptor for advanced
glycation endproduct (RAGE).--

--39. (New) The method of claim 1, wherein the agent is soluble
receptor for advanced glycation endproduct (sRAGE).--

--40. (New) The method of claim 1, wherein the agent is an
antibody or portion thereof capable of specifically
binding to RAGE.--

--41. (New) The method of claim 40, wherein the antibody is a

Applicants: David Stern and Ann-Marie Schmidt
Serial No.: 08/905,709
Filing Date: August 5, 1997
Page 4

monoclonal antibody.--

CMX
E4
--42. (New)The method of claim 40, wherein the antibody is a polyclonal antibody.--

--43. (New)The method of claim 40, wherein the portion of the antibody is a complementarity determining region.--

--44. (New)The method of claim 40, wherein the portion of the antibody is a variable region.--

--45. (New)The method of claim 40, wherein the portion of the antibody is an Fab portion.--

--46. (New)The method of claim 1, wherein the polypeptide is admixed with a pharmaceutically acceptable carrier.--

REMARKS

Claims 1-10, 12, 13, 15-27, 29, 30 and 32-35 are pending in the subject application. Applicants have hereinabove canceled claims 5-7, 10, 12, 13, 19-27, 29, 30 and 32-35 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a later-filed application. Further, applicants have amended claims 1 and 15-18 and added new claims 36-45. Support may be found inter alia in the specification as follows: claim 1: page 16, line 35 ad page 17, lines 1-8; claim 15: page 6, lines 6-9; claim 16: page 6, lines 9-12; claim 17: page 6, lines 14-17;